Analysts anticipate Valeant to post $2.1B in quarterly sales — 4 insights

Written by Eric Oliver | February 05, 2018 | Print  |

Zacks Investment Research believes Valeant Pharmaceuticals will post $2.17 billion in sales for the current financial quarter, Stock News Times reports.

Here's what you should know:

1. Five analyst firms made predictions on Valeant's quarterly sales, the lowest estimate was $2.09 billion, while the highest was $2.24 billion.

2. If the estimates are correct, it shows Valeant sales decreased 9.6 percent year over year.

3. Valeant will announce its quarterly earnings Feb. 27.

4. Analysts anticipate full-year sales between $8.65 billion to $8.80 billion.

More articles on supply chain:  
Campbell Clinic receives 8-year tax abatement for $30M expansion with ASC — 4 insights
Maximize your 2018 reimbursements: Know your health plans, know your market, and stay on top of trends
21 statistics on ASC accounts receivable

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.